KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Receivables - Other (2023 - 2026)

TherapeuticsMD filings provide 8 years of Receivables - Other readings, the most recent being $3.2 million for Q1 2026.

  • On a quarterly basis, Receivables - Other rose 7.18% to $3.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 7.18% increase, with the full-year FY2025 number at $3.5 million, down 1.04% from a year prior.
  • Receivables - Other hit $3.2 million in Q1 2026 for TherapeuticsMD, down from $3.5 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $21.6 million in Q4 2023 to a low of $2.9 million in Q2 2024.
  • Median Receivables - Other over the past 4 years was $3.4 million (2024), compared with a mean of $5.2 million.
  • Biggest five-year swings in Receivables - Other: crashed 83.49% in 2024 and later grew 28.71% in 2025.
  • TherapeuticsMD's Receivables - Other stood at $21.6 million in 2023, then crashed by 83.49% to $3.6 million in 2024, then fell by 1.04% to $3.5 million in 2025, then fell by 8.91% to $3.2 million in 2026.
  • The last three reported values for Receivables - Other were $3.2 million (Q1 2026), $3.5 million (Q4 2025), and $3.7 million (Q3 2025) per Business Quant data.